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Abstract
Introduction and objective. Continuous subcutaneous insulin infusion (CSII) via personal insulin pump is a valuable 
therapeutic tool in T1DM patients. However, adherence to recommended CSII- related behaviours may be of concern to 
young adults with intensive, variable daily activities (students, young professionals). The aim of this observational study was 
to estimate treatment outcomes in young adult patients with T1DM, and compare them with older individuals.
Materials and methods. Overall, 140 adults with T1DM on CSII were examined, divided into 2 subgroups: 77 patients 
younger than 26 years of age (mean 20.6 years) and 63 older subjects (mean 39.0). We compared the glycaemic control in 
both groups of T1DM subjects and analyzed treatment attitudes to identify potentially modifiable behaviours influencing 
the efficacy of the treatment.
Results. The younger individuals were characterized by significantly worse treatment outcomes, compared to the older 
ones: the mean HbA1c levels were 7.6 ± 1.3% and 6.9±1.3% (p=0.00001), while the mean glucose levels based on glucometer 
downloads were 161±33.6 mg/dL and 136±21.8 mg/dL (p=0.00001), respectively. The frequency of self-monitoring of blood 
glucose (SMBG) was lower in younger individuals (5.3±2.1 vs. 7.0±2.8 daily, p=0.0005, respectively); they were also less 
frequently used advanced pump functions, e.g. the bolus calculator (48% vs. 67% users, p=0.0014, respectively).
Conclusions. The efficacy of CSII treatment observed in young T1DM adults was worse than in older patients. The reason 
for this phenomenon remains unclear, it may be due simply to age-dependend behaviours, to social environment, or both.
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IntRoduCtIon
Diabetes Control and Complications Trial (DCCT) [1] 
has highlighted the importance of intensive therapy in 
achieving tight metabolic control and improving long-term 
health outcomes in patients with Type 1 Diabetes Mellitus 
(T1DM). The release of the DCCT has also renewed interest 
in the role of continuous subcutaneous insulin infusion 
(CSII) via personal insulin pump in improving efficacy of 
diabetes treatment. It has become apparent that the use 
of insulin pump therapy has many potential benefits for 
T1DM patients, because it offers a more physiological way 
of insulin administration [2, 3, 4, 5, 6, 7]. CSII delivers a 
variable reprogrammable basal rate of fast/rapid acting 
insulin delivered as a background insulin with bolus doses 
to cover the intake of carbohydrate containing foods, and 
to correct high blood glucose levels. This system of insulin 
delivery appears to offer not only improvement in metabolic 
control, but also increased physiological and psychological 
wellbeing [2, 3, 4, 5, 6, 7]. Improvement in lifestyle may 
be the most important reason for the patient who chooses 
CSII, with the ability to increase flexibility in moment-to-
moment living [8, 9]. However, it is not clear whether this 
treatment is equally effective in different patient subgroups, 
and if all patients may benefit from CSII to the same degree 
[10]. Especially, adherence to recommended CSII- related 
behaviors, crucial in achieving good metabolic control [11], 
may be of concern in young adults with intensive, variable 
daily activities (students, young professionals). The aim of 
this observational study was to estimate treatment outcomes 
in young adult patients with T1DM treated with CSII, and 
compare them with older individuals.
MAteRIAls And Methods
Overall, 140 adults with T1DM on CSII were examined; 
they were divided into two subgroups: 77 patients younger 
than 26 years of age (range 18-26 years, mean 20.7 years) 
and 63 older subjects (range 26.5-75.5 years, mean 39.0). 
Type 1 diabetes was diagnosed either on the basis of typical 
clinical symptoms (younger individuals), or on combined 
clinical (signs of absolute insulin deficiency) and biochemical 
criteria (low or undetectable C-peptide level, presence of 
GAD autoantibodies). All younger individuals were pre-
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college and college students, or were at the onset of their 
professional careers. In contrast to individuals older than 
26 years, the younger ones were also the beneficiaries of 
reimbursement of insulin pump therapy. Those who failed 
to meet reimbursement criteria and who paid for the insulin 
pump out of their own pockets were qualified for CSII 
therapy, mostly on the patient’s request, with the aim of 
improving quality of life and increase therapy safety. This 
also concerned the oldest patients (above 65 years of age). 
The younger subgroup was characterized by shorter diabetes 
duration (10.0 years vs. 17.7 years, p=0.0000). The groups did 
not differ with respect to BMI (22.8 kg/m2 in young T1DM 
subjects vs. 23.7 kg/m2 in older patients, p=0.07), gender 
(p=0.83), and time spend on CSII (4.4 years vs. 4.3 years, 
p=0.42). Individuals with less than a 3-month history of CSII 
treatment were excluded from the analysis. We compared 
the glycaemic control in both groups of T1DM subjects 
and analyzed treatment attitudes to identify potentially 
modifiable behaviours influencing the efficacy of the 
treatment. The available insulin pump and blood glucose 
meter downloads, as well as HbA1c level, were reviewed. 
We analyzed records of insulin pumps from the last 4-6 
weeks, while for glucometers the whole memory content (200-
300 records, depending on glucometer type) was included. 
Statistical analysis was performed with the use of statistical 
package Statistica10.0 PL using the t-Student test or, if the 
assumptions of the parametric method were not satisfied, 
the non-parametric U Mann-Whitney test was applied. The 
variables were presented by means, standard deviations 
or frequency if appropriate. Difference was considered 
statistically significant when p<0.05.
Results
Younger individuals were characterized by significantly 
worse treatment outcomes, compared to older ones: the mean 
HbA1c levels were 7.6 ± 1.3% and 6.9 ± 1.3% (p=0.0000), while 
the mean glucose levels based on glucometer downloads 
were 161 ± 33.6 mg/dL and 136 ± 21.8 mg/dL (p=0.0000), 
respectively. Of interest, there were no differences in glucose 
variability (SD/x mean x 100%) between the 2 groups (46.7 
± 9.1% vs. 44.3 ±8.2%, for younger and older individuals, 
respectively, p=0.1498). The number of hypoglycemic episodes 
(defined as glycaemia < 55 mg/dL) for 100 measurements was 
higher in older vs. younger patients (6.2 ± 4.9 and 4.5 ± 4.0, 
respectively, p=0.0352).
The frequency of self-monitoring of blood glucose (SMBG) 
was lower in younger individuals (5.3 ± 2.1 vs. 7.0 ± 2.8 daily, 
p=0.0005, respectively), they were also less frequently using 
advanced insulin pump options like the bolus calculator (48% 
vs. 67% users, p=0.0014, respectively), dual/square boluses 
(10% vs. 23% users, p=0.194, respectively), and continuous 
glucose monitoring (CGM) systems (14% vs. 31%, p=0.155, 
respectively).
dIsCussIon
For reasons that remain unclear, the efficacy of CSII 
treatment observed in young T1DM adults was worse, 
compared to older patients. Clinicians treating young 
adults with T1D must recognize that progressing through 
adolescence to adulthood and having diabetes are individually 
difficult processes that are linked and complicated by one 
another [12, 13, 14, 15, 16]. CSII allows the patient to modify 
insulin availability hour-by-hour, which makes possible the 
performance of activities that would otherwise be risky: 
delaying meals or missing them altogether, sleeping late 
at weekends, engaging in vigorous exercise, working late 
at night or working on shifts [11]. One may speculate that 
all these behaviours may lead to worsening of metabolic 
control; however, it is very difficult to estimate their role in 
an objective manner; this, anyway, was also not the subject 
of this study. The ‘objective’ parameters that could influence 
metabolic control, and which were different for younger and 
older individuals, were SMBG frequency (lower in younger 
group) and the usage of an advanced insulin pump options 
(also lower in younger group). Both procedures, undoubtedly 
leading to the improvement of diabetes control [11, 17, 18, 
19, 20], are time-consuming, and this may be the reason 
why younger individuals – students or those who are at the 
onset of their professional careers – meaning those who 
are engaged in establishing funds for their future life, are 
more reluctant to use them. The reluctance in using these 
time-consuming procedures may also be due simply to age-
dependent patterns of behaviour [12, 13, 14, 15].
One can also not exclude that the reimbursement system 
can affect a patient’s attitude towards treatment. Insulin 
pumps and disposables are reimbursed for individuals 
younger than 26 years of age in Poland, whereas older 
patients must cover all the CSII-related cost out of their own 
pockets. One can speculate that patients who directly pay for 
insulin pump usage are more determined to use all available 
options to improve therapy outcomes. It should be the task 
for therapeutic teams to show young CSII treated patients 
all the benefits of both SMBG, and the usage of advanced 
insulin pump functions.
table 1. Characteristics of study groups and use of insulin pump tools 
and options
Characteristics 26- (n=77) 26+ (n=63) p
HbA1c level [%] 7.6 +1.3 6.9 ± 1.3 0.0000
Mean Glycaemia [mg/dl] 161.9 ± 33.6 136.0 ± 21.8 0.0000
No. blood glucose monitoring per day [n] 5.3 ± 2.1 7.0 ± 2.8 0.0005
Glycaemia variability [%] 46.7 ± 9.1 44.3 ± 8.2 0.1498
Gender M/F [n] 22 / 55 17 / 46 0.83
BMI [kg/m2] 22.8 ± 2.2 23.7 ± 2.9 0.07
Age [yr] 20.7 ± 2.4 39.0 ± 11.4 0.0000
Diabetes duration [yr] 10.0 ± 4.2 17.7 ± 8.9 0.0000
Time on CSII [yr] 4.4 ± 2.5 4.3 ± 3.3 0.42
Daily insulin doses [IU] 48.7 ± 10.4 44.2 ±13.2 0.0084
No. boluses per Day [n] 6.0 ± 2.5 6.6 ± 2.8 0.36
Percent of basal insulin [%] 40.3 ± 10.4 41.0 ± 7.8 0.68
No. of hypoglycaemia per 100 
measurements [n]
4.5 ± 4 6.2 ± 4.9 0.0352
Use of bolus calculator function Yes/No [n] 31 / 46 43 / 21 0.0014
Use of CGMS option Yes/No [n] 11 / 66 20 / 44 0.0155
Use of dual-wave /square bolus function 
Yes/No [n]
7 / 70 15 / 49 0.0194 
Data are mean ± SD. CGMS: Continuous Glucose Monitoring
System, IU: international unit.
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Another ‘objective, and perhaps a surprising finding 
of our study, was the higher number of hypoglycemia 
per 100 measurements. This may be due simply to more 
strict glycaemic control, to a higher number of SMBG 
measurements in this group, or due to more frequent bolus 
administration.
ConClusIon
The efficacy of CSII treatment observed in young T1DM 
adults was worse, compared to older patients. The reason 
for this phenomenon remains unclear, it may be due simply 
to age-dependent behaviours, to the social environment, or 
both. The younger group was characterized not only by lower 
SMBG frequency and less frequent use of advanced insulin 
pump options, but also by a lower number of hypoglycaemia 
per 100 measurements.
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